N-of-1 trials: The epitome of personalized medicine?

Observational studies are notoriously susceptible to bias, and parallel-group randomized trials are important to identify the best overall treatment for eligible patients. Yet, such trials can be expected to be a misleading indicator of the best treatment for some subgroups or individual patients. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Samuel, Joyce P., Wootton, Susan H., Tyson, Jon E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Special Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388431/
https://www.ncbi.nlm.nih.gov/pubmed/37528940
http://dx.doi.org/10.1017/cts.2023.583
_version_ 1785082112240517120
author Samuel, Joyce P.
Wootton, Susan H.
Tyson, Jon E.
author_facet Samuel, Joyce P.
Wootton, Susan H.
Tyson, Jon E.
author_sort Samuel, Joyce P.
collection PubMed
description Observational studies are notoriously susceptible to bias, and parallel-group randomized trials are important to identify the best overall treatment for eligible patients. Yet, such trials can be expected to be a misleading indicator of the best treatment for some subgroups or individual patients. In selected circumstances, patients can be treated in n-of-1 trials to address the inherent heterogeneity of treatment response in clinical populations. Such trials help to accomplish the ultimate goal of all biomedical research, to optimize the care of individual patients.
format Online
Article
Text
id pubmed-10388431
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-103884312023-08-01 N-of-1 trials: The epitome of personalized medicine? Samuel, Joyce P. Wootton, Susan H. Tyson, Jon E. J Clin Transl Sci Special Communications Observational studies are notoriously susceptible to bias, and parallel-group randomized trials are important to identify the best overall treatment for eligible patients. Yet, such trials can be expected to be a misleading indicator of the best treatment for some subgroups or individual patients. In selected circumstances, patients can be treated in n-of-1 trials to address the inherent heterogeneity of treatment response in clinical populations. Such trials help to accomplish the ultimate goal of all biomedical research, to optimize the care of individual patients. Cambridge University Press 2023-07-03 /pmc/articles/PMC10388431/ /pubmed/37528940 http://dx.doi.org/10.1017/cts.2023.583 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Special Communications
Samuel, Joyce P.
Wootton, Susan H.
Tyson, Jon E.
N-of-1 trials: The epitome of personalized medicine?
title N-of-1 trials: The epitome of personalized medicine?
title_full N-of-1 trials: The epitome of personalized medicine?
title_fullStr N-of-1 trials: The epitome of personalized medicine?
title_full_unstemmed N-of-1 trials: The epitome of personalized medicine?
title_short N-of-1 trials: The epitome of personalized medicine?
title_sort n-of-1 trials: the epitome of personalized medicine?
topic Special Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388431/
https://www.ncbi.nlm.nih.gov/pubmed/37528940
http://dx.doi.org/10.1017/cts.2023.583
work_keys_str_mv AT samueljoycep nof1trialstheepitomeofpersonalizedmedicine
AT woottonsusanh nof1trialstheepitomeofpersonalizedmedicine
AT tysonjone nof1trialstheepitomeofpersonalizedmedicine

Ejemplares similares